Table 2. Ki-67, SUV_max and SUV_mean 40% isodose values.

			SUVmax			SUVmean 40% isodose
Patient no.	Path response	Ki-67 Baseline	Baseline	Post 1 cycle NAC	% change	Baseline	Post 1 cycle NAC	% change
1	NR	44.7	6.05	2.66	−56.03	3.2	1.3	−59.38
2	PR	60.7	13.87	14.15	2.02	8.3	8.4	1.20
3	Near pCR	21.1	11.47	4.3	−62.51	5.5	2.2	−60.00
4	NR	2.3	2.92	1.98	−32.19	1.6	1	−37.50
5	NR	9.2	6.59	3.98	−39.61	3.4	2.2	−35.29
6	Near pCR	16.5	4.07	4.05	−0.49	2.2	2.2	0
7	PR	a	3.19	3.55	11.29	1.7	1.8	5.88
8	pCR	40.8	7.39	5.32	−28.01	4	2.6	−35.00
9	Near pCR	23.8	4.96	3.13	−36.90	2.8	1.6	−42.86
10	NR	28.8	7.91	5.2	−34.26	4.5	3	−33.33
11	PR	13.7	5.83	6.3	8.06	3.4	3.7	8.82
12	PR	32.4	6.116	3	−50.95	3.2	1.5	−53.13
13	PR	16	3.53	a	a	1.9	a	a
14	NR	29.8	12.86	5.45	−57.62	7.9	3.4	−56.96
15	Near pCR	42.6	6.36	4.16	−34.59	3.5	2.2	−37.14
16	PR	22.1	4.8	a	a	2.5	a	a
17	Near pCR	54.1	5.45	2.3	−57.80	2.8	1.2	−57.14
18	a	68.4	11.44	a	a	7.2	a	a
19	pCR	59.5	13	8.46	−34.92	8.2	5.4	−34.15
20	NR	25.8	8.21	4.57	−44.34	4.3	2.5	−41.86

Abbreviations: NAC=neoadjuvant chemotherapy; NR=no response; pCR=pathological complete response; PR=pathological response; SUV=standardised uptake value.

^aData not available.